Have you or a loved one undergone treatment for AL Amyloidosis without success?
Join the Future of AL Amyloidosis Treatment
Be part of a groundbreaking clinical trial exploring the potential of NXC-201, a cutting-edge CAR-T therapy designed for relapsed and refractory AL Amyloidosis.
About the NEXICART-2 Clinical Trial
ClinicalTrial.gov Identifier: NCT06097832
The NEXICART-2 clinical trial is dedicated to evaluating the safety and efficacy of our investigational CAR-T cell therapy (NXC-201) for patients with relapsed and refractory AL Amyloidosis. Participants can expect comprehensive care throughout the trial, including regular health assessments, monitoring, and support from our experienced medical team. By participating in the trial, you take an active role in allowing us to gather valuable research and data to advance the treatment of AL Amyloidosis with the goal of improving patient outcomes.
Understanding AL Amyloidosis
AL Amyloidosis is a rare and serious condition characterized by the buildup of amyloid proteins in organs and tissues, leading to organ dysfunction and severe health complications. These abnormal proteins, produced by dysfunctional plasma cells, can accumulate in the heart, kidneys, liver, spleen, nervous system, and digestive tract, impairing their function.
Patients with AL Amyloidosis often experience symptoms such as fatigue, swelling, weight loss, shortness of breath, and numbness or tingling in the extremities. The disease is particularly challenging because it often goes undiagnosed until it reaches an advanced stage, making early and effective treatment crucial.
Current treatments for AL Amyloidosis primarily involve chemotherapy and stem cell transplants, but many patients do not respond adequately to these therapies. This highlights the urgent need for new treatment options that can provide better outcomes for patients struggling with this debilitating disease.
Introducing NXC-201: A New Approach to Treating AL Amyloidosis
NXC-201 is an investigational CAR-T cell therapy designed to offer a new treatment option for patients with relapsed and refractory AL Amyloidosis. This innovative therapy harnesses the power of the patient’s own immune system to target and destroy the abnormal plasma cells responsible for producing amyloid proteins.
How It Works
CAR-T therapy involves collecting and modifying a patient’s T-cells, a type of immune cell, to express a chimeric antigen receptor (CAR) that specifically targets the disease-causing cells. Once these engineered CAR-T cells are infused back into the patient, they seek out and eliminate the amyloid-producing plasma cells, reducing the amyloid buildup and potentially restoring organ function.
Potential Benefits
NXC-201 represents a promising new direction in the treatment of AL Amyloidosis, offering potential to improve outcomes in patients who have exhausted other treatment options.
Eligibility Requirements for NEXICART-2 Clinical Trial
To participate in the NEXICART-2 clinical trial, patients must meet certain eligibility criteria. These criteria ensure that the trial is safe and appropriate for each participant and that the data collected will be scientifically valid.
This is not a full list of inclusion criteria and each case will be evaluated individually to be considered for the trial
Important Considerations
Other Medical Conditions: Patients with certain other medical conditions may not be eligible to participate. These conditions will be reviewed during the screening process.
Previous Therapies: Prior treatments and their outcomes will be considered to determine eligibility.
Commitment: Participants must be willing to comply with study procedures, including visits to the clinical trial site for monitoring and assessments.
If you or a loved one meets these criteria and is interested in participating in the NXC-201 clinical trial, please contact us to learn more about the enrollment process.
How to Enroll in the NEXICART-2 Clinical Trial
Enrolling in the NEXICART-2 clinical trial is a straightforward process designed to ensure that potential participants receive all the information they need and are fully supported throughout their journey.
For more information or to begin the enrollment process, please contact our clinical trial team at:
Patient Resources
At Immix Biopharma, we are committed to providing comprehensive support and resources to patients participating in the NEXICART-2 clinical trial. We understand that navigating a clinical trial can be challenging, and we are here to ensure that you have access to all the information and assistance you need.
Additional Resources
Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives